NICE Guidelines - COPD

Session Objectives

  • Review NICE guidelines for managing Chronic Obstructive Pulmonary Disease (COPD)

Overview of COPD

  • Characteristics

    • COPD is marked by airflow obstruction.

    • Major cause: Smoking; occupational exposure is also significant.

    • Defined by:

      • FEV1 < 80% predicted

      • FEV1/FVC < 0.7

  • Prevalence

    • Third leading cause of respiratory deaths (following pneumonia and lung cancer).

    • Accounts for 20% of respiratory mortality.

    • 1 in 8 emergency hospitalizations may be attributed to COPD.

    • Estimated annual costs to NHS:

      • Direct costs: £491,652,000

      • Total costs (direct + indirect): £982,000,000

Diagnosis of COPD

  • Key indicators

    • Absence of asthma features

    • Age over 35

    • Current or former smoker

    • Symptoms:

      • Wheezing

      • Regular sputum production

      • Exertional breathlessness

      • Chronic cough

      • Frequent ‘winter bronchitis’

  • Diagnosis Process

    • Perform spirometry if COPD is suspected:

      • Airflow obstruction criteria: FEV1 < 80% predicted; FEV1/FVC < 0.7

    • Reversibility testing is not always necessary at this stage.

    • If uncertain:

      • Normalization of FEV1 post-pharmacological treatment.

      • Significant FEV1 response to bronchodilators.

      • Variability in peak flow measurements.

      • If still uncertain, refer for additional investigation.

Clinical Features: COPD vs Asthma

  • Smoking

    • Asthma: Almost all cases

    • COPD: Most cases are related to smoking

  • Age

    • Asthma: Rare under 35

    • COPD: Commonly diagnosed after 35

  • Cough and Breathlessness

    • Asthma: Chronic productive cough uncommon

    • COPD: Chronic productive cough very common; breathlessness progressive and persistent

  • Symptom Variation

    • Asthma: Less common variability

    • COPD: Very common variability in symptoms

Assessment of Severity

  • Assessment Components

    • Spirometry tests

    • Assessment of breathlessness (MRC dyspnoea scale)

    • Frequency of exacerbations

    • Body mass index (BMI)

  • MRC Dyspnoea Scale

    • Grade 1: No breathlessness except on strenuous exercise

    • Grade 2: Shortness of breath while walking a small hill

    • Grade 3: Walks slower due to breathlessness

    • Grade 4: Shortness of breath after a few minutes of walking

    • Grade 5: Shortness of breath at rest

  • Airflow Severity by FEV1 Predicted

    • Mild: 50 – 80%

    • Moderate: 30 – 49%

    • Severe: <30%

    • Refer for investigation if:

      • Suspected severe COPD (FEV1 <30%)

      • Cor pulmonale

      • Dysfunctional breathing

      • Young age or family history of deficiency

      • Frequent infections or hemoptysis

Patient Follow-up in Primary Care

  • Primary Focus Areas

    • Smoking status and quitting desire

    • Symptom control effectiveness:

      • Breathlessness, exercise tolerance, frequency of exacerbations

    • Complications presence

    • Effects and administration of drug treatments

    • Inhaler technique assessment

    • Need for referrals to specialists

    • Potential for pulmonary rehabilitation

    • Monitor cor pulmonale symptoms and long-term oxygen therapy needs

    • Patient's nutritional state and potential depression

    • Consider involvement of Social Services and Occupational Therapy in care

Management of Stable COPD

  • Management Strategies

    • Comprehensive patient assessment (symptoms, smoking, exacerbations, BMI)

    • Multidisciplinary team involvement is crucial

  • Breathlessness Management

    • Discontinue ineffective therapies

    • Implement short-acting bronchodilators as needed

    • If symptoms persist, combine medications or escalate to long-acting bronchodilators and corticosteroids if necessary

    • Consider pulmonary rehabilitation for functionally disabled patients and potential referrals for surgical interventions (bullectomy, LVRS, transplantation)

Key Considerations

  • Diagnosis

  • Importance of smoking cessation

  • Utilization of inhaled therapies

  • Implementation of pulmonary rehabilitation

  • Management of exacerbations

  • Emphasis on multidisciplinary healthcare approach

Conclusion

  • Contact Information

    • Blessing Ukoha-Kalu

    • Email: blessing.ukoha-kalu@nottingham.ac.uk